Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342317 | 0.88 | LTA4H (0.81) | LTA4HMEN1KMT2AMMP2MMP3 | |
| SCHEMBL15233235 | 0.85 | — | — | |
| SCHEMBL23462 | 0.85 | — | — | |
| SCHEMBL15903694 | 0.85 | LTA4H (0.59) | LTA4HMEN1KMT2AMMP2MMP3 | |
| Methane SCHEMBL27485154 | 0.83 | PTGS1 (0.53) | LTA4HMEN1KMT2APTGS1IDO1 | |
| SCHEMBL9107231 | 0.83 | LTA4H (0.51) | LTA4HEPHX2SOS1HSPB1MAOB | |
| SCHEMBL11328636 | 0.82 | CYP4F2 (0.53) | LTA4HMEN1KMT2AEPHX2SOS1 | |
| SCHEMBL713596 | 0.81 | MAOB (0.67) | MEN1KMT2AMAOBAPPNR4A2 | |
| SCHEMBL2351004 | 0.81 | LTA4H (0.53) | LTA4HEPHX2 | |
| Ethylene SCHEMBL27825958 | 0.80 | PTGS1 (0.52) | MEN1KMT2APTGS1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103347864-B | Pyrimidone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA 2 | 葛兰素集团有限公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| CN-104478812-A | Pyrimidone compound for treating Lp-PLA2-mediated diseases or illness | GLAXO GROUP LTD | 2015-04-01 | — | — | CN | disclosed |
| US-6420415-B1 | Thiol compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1132379-A1 | NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-0846687-B1 | Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors | LILLY CO ELI (US) | 2001-08-08 | — | — | EP | disclosed |
| US-5972972-A | FOR TREATMENT OF SEPTIC SHOCK, ADULT RESPIRATORY DISTRESS SYNDROME, PANCREATITIS, TRAUMA-INDUCED SHOCK, BRONCHIAL ASTHMA, ALLERGIC RHINITIS, RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0711271-B1 | AMINOINDANES AND RELATED COMPOUNDS USEFUL AS CALCIUM-CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-07 | — | — | EP | disclosed |
| WO-1998024437-A1 | PYRAZOLES AS HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0846687-A1 | Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY (US) | 1998-06-10 | — | — | EP | disclosed |
| CN-1131414-A | Aminoindanes and related compounds useful as calcium channel antagonists | SMITHKLINE BEECHAM PLC (GB) | 1996-09-18 | — | — | CN | disclosed |
| EP-0711271-A1 | AMINOINDANES AND RELATED COMPOUNDS USEFUL AS CALCIUM-CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004027-A1 | AMINOINDANES AND RELATED COMPOUNDS USEFUL AS CALCIUM-CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | LTA4H 18/4885MEN1 2195/4885KMT2A 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.